Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2024-11-26 Sale | 2024-11-27 5:20 pm | ALNYLAM PHARMACEUTICALS INC. | ALNY | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | 3,000 | $251.65 | $754,947 | 13,418 (Indirect Direct) | View |
2024-08-12 Sale | 2024-08-14 4:12 pm | ALNYLAM PHARMACEUTICALS INC. | ALNY | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | 22,025 | $270.99 | $5,968,516 | 15,610 (Indirect Direct) | View |
2024-06-25 Sale | 2024-06-26 4:26 pm | ALNYLAM PHARMACEUTICALS INC. | ALNY | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | 1,198 | $230.99 | $276,731 | 14,718 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-12-12 Option Award | 2024-12-16 4:15 pm | N/A 2034-12-11 | Ovid Therapeutics Inc. | OVID | Fitzgerald Kevin Joseph Director | 90,000 | $0 | 90,000 (Direct) | View |
2024-11-25 Option Award | 2024-11-27 5:20 pm | N/A N/A | ALNYLAM PHARMACEUTICALS INC. | ALNY | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | 3,000 | $0 | 13,418 (Direct) | View |
2024-08-12 Exercise | 2024-08-14 4:12 pm | N/A N/A | ALNYLAM PHARMACEUTICALS INC. | ALNY | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | 6,667 | $97.72 | 15,610 (Direct) | View |
2024-08-12 Exercise | 2024-08-14 4:12 pm | N/A 2029-02-28 | ALNYLAM PHARMACEUTICALS INC. | ALNY | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | 20,725 | $0 | 15,610 (Direct) | View |
2024-08-12 Exercise | 2024-08-14 4:12 pm | N/A N/A | ALNYLAM PHARMACEUTICALS INC. | ALNY | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | 14,058 | $85 | 15,610 (Direct) | View |
2024-06-24 Option Award | 2024-06-26 4:26 pm | N/A N/A | ALNYLAM PHARMACEUTICALS INC. | ALNY | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | 2,498 | $0 | 14,718 (Direct) | View |
Ownership | 2024-03-28 4:17 pm | N/A N/A | ALNYLAM PHARMACEUTICALS INC. | ALNY | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | 0 | $0 | 124,620 (Direct) | View |
2024-02-22 Option Award | 2024-02-26 5:56 pm | N/A 2034-02-21 | Ovid Therapeutics Inc. | OVID | Fitzgerald Kevin Joseph Director | 30,000 | $0 | 30,000 (Direct) | View |
2023-02-23 Option Award | 2023-02-27 4:51 pm | N/A 2033-02-22 | Ovid Therapeutics Inc. | OVID | Fitzgerald Kevin Joseph Director | 15,000 | $0 | 15,000 (Direct) | View |
2022-02-03 Option Award | 2022-02-04 8:49 pm | N/A 2032-02-02 | Ovid Therapeutics Inc. | OVID | Fitzgerald Kevin Joseph Director | 15,000 | $0 | 15,000 (Direct) | View |
2021-10-06 Option Award | 2021-10-07 4:44 pm | N/A 2031-10-05 | Ovid Therapeutics Inc. | OVID | Fitzgerald Kevin Joseph Director | 30,000 | $0 | 30,000 (Direct) | View |